Skip to main content
SpringerLink
Log in

Quadruple Regimens for Helicobacter pylori Infection

  • Chapter
  • First Online:
Helicobacter pylori

  • 1530 Accesses

Abstract

An effective therapy against Helicobacter pylori (H. pylori) is defined as one achieving at least a 90 % eradication rate. Treatment results are best when reliable schemes are based on susceptibility testing; however, empiric eradication therapies are generally prescribed. Standard triple therapy has been the most recommended regimen, but its efficacy is currently suboptimal worldwide due to rising clarithromycin resistance. Consequently, the scientific community has recently taken on the task of rescuing old empiric quadruple regimens to overcome antibiotic resistance.

The choice of empiric therapy may depend on patient previous antibiotic treatment, local patterns of antibiotic resistance, and drug availability. Currently, the preferred first-line choices are bismuth quadruple therapy and non-bismuth quadruple concomitant therapy. A 14-day bismuth quadruple therapy is expected to have a 95 % efficacy regardless of metronidazole resistance, but its Achilles heel is compliance, besides drug availability. On the contrary, the efficacy of concomitant therapy is challenged by dual clarithromycin and metronidazole resistance. Optimization of all regimens (increased duration, adequate proton pump inhibitor and antibiotic doses, and dosing intervals) is indispensable to maximize their efficacy. Treatment failures should be managed with an alternate regimen using an optimized combination of different antibiotics. Bismuth-containing fluoroquinolone quadruple therapy and bismuth quadruple therapy (if not used previously) have recently shown the best results. Due to regional variation in H. pylori resistance patterns, the golden rule for choice of treatment is only to use therapies that work locally (>90–95 % success) and to monitor their effectiveness over time.

Disclosure Statement:

The author has no conflict of interest to declare.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–5.

    Article  CAS  PubMed  Google Scholar 

  2. Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014;20:5191–204. doi:10.3748/wjg.v20.i18.5191.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol. 2013;23:492–501. doi:10.1016/j.semcancer.2013.07.004.

    Article  CAS  PubMed  Google Scholar 

  4. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–53. doi:10.1136/gut.2009.192757.

    Article  CAS  PubMed  Google Scholar 

  5. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: Evidence based medicine rather than medicine based evidence. Clin Gastroenterol Hepatol. 2014;12:177–86. doi:10.1016/j.cgh.2013.05.028.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American college of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–25.

    Article  CAS  PubMed  Google Scholar 

  7. Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III consensus report. Gut. 2007;56:772–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific conference. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–600. doi:10.1111/j.1440-1746.2009.05982.x.

    Article  PubMed  Google Scholar 

  9. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1–20. doi:10.1111/j.1523-5378.2009.00738.x.

    Article  CAS  PubMed  Google Scholar 

  10. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence consensus report. Gut. 2012;61:646–64. doi:10.1136/gutjnl-2012-302084.

    Article  CAS  PubMed  Google Scholar 

  11. Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, et al. III Spanish consensus conference on Helicobacter pylori infection. Gastroenterol Hepatol. 2013;36:340–74. doi:10.1016/j.gastrohep.2013.01.011.

    Article  PubMed  Google Scholar 

  12. Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori, Liu WZ, Xie Y, Cheng H, Lu NH, Hu FL, Zhang WD, et al. Fourth Chinese national consensus report on the management of Helicobacter pylori infection. J Dig Dis. 2013;14:211–21. doi:10.1111/1751-2980.12034.

    Article  Google Scholar 

  13. Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Korean College of Helicobacter and Upper Gastrointestinal Research, et al. J Gastroenterol Hepatol. 2014;29:1371–86. doi:10.1111/jgh.12607.

    Article  PubMed  Google Scholar 

  14. Gisbert JP. Is culture necessary before first-line treatment for Helicobacter pylori infection? Intern Med. 2011;50:2717.

    Article  PubMed  Google Scholar 

  15. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275–8.

    Article  PubMed  Google Scholar 

  16. Borody TJ, Cole P, Noonan S, Morgan A, Lenne J, Hyland L, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust. 1989;151:431–5.

    CAS  PubMed  Google Scholar 

  17. Megraud F. The challenge of Helicobacter pylori resistance to antibiotics: The comeback of bismuth-based quadruple therapy. Ther Adv Gastroenterol. 2012;5:103–9. doi:10.1177/1756283X11432492.

    Article  CAS  Google Scholar 

  18. Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 2014;20:10338–47. doi:10.3748/wjg.v20.i30.10338.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor based triple therapy for Helicobacter pylori eradication: A meta-analysis. Helicobacter. 2008;13:532–41. doi:10.1111/j.1523-5378.2008.00643.x.

    Article  PubMed  Google Scholar 

  20. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: A meta analysis of randomized clinical trials. PLoS One. 2013;8:e62162. doi:10.1371/journal.pone.0062162.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12, CD008337. doi:10.1002/14651858.CD008337.pub2.

    PubMed  Google Scholar 

  22. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y, Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–42. doi:10.1136/gutjnl-2012-302254.

    Article  CAS  PubMed  Google Scholar 

  23. Prasertpetmanee S, Mahachai V, Vilaichone RK. Improved efficacy of proton pump inhibitor – Amoxicillin – Clarithromycin triple therapy for Helicobacter pylori eradication in low Clarithromycin resistance areas or for tailored therapy. Helicobacter. 2013;18:270–3. doi:10.1111/hel.12041.

    Article  CAS  PubMed  Google Scholar 

  24. Zullo A, Rinaldi V, Winn S, Meddi P, Lionetti R, Hassan C, Ripani C, Tomaselli G, Attili AF. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000;14:715–8.

    Article  CAS  PubMed  Google Scholar 

  25. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: A pooled-data analysis. Gut. 2007;56:1353–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Jafri NS, Hornung CA, Howden CW. Meta-analysis: Sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med. 2008;148:923–31.

    Article  PubMed  Google Scholar 

  27. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: Systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009;104:3069–79. doi:10.1038/ajg.2009.555.

    Article  CAS  PubMed  Google Scholar 

  28. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Sequential therapy for Helicobacter pylori eradication in children. Aliment Pharmacol Ther. 2012;36:534–41. doi:10.1111/j.1365-2036.2012.05229.x.

    Article  CAS  PubMed  Google Scholar 

  29. Yoon H, Lee DH, Kim N, Park YS, Shin CM, Kang KK, Oh DH, Jang DK, Chung JW. Meta-analysis: Is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol. 2013;28:1801–9. doi:10.1111/jgh.12397.

    Article  PubMed  Google Scholar 

  30. Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D. Standard triple and sequential therapies for Helicobacter pylori eradication: An update. Eur J Intern Med. 2013;24:16–9. doi:10.1016/j.ejim.2012.07.006.

    Article  PubMed  Google Scholar 

  31. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy. BMJ. 2013;28:1801–9. doi:10.1136/bmj.f4587.

    Google Scholar 

  32. Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential therapy or standard triple therapy for Helicobacter pylori infection: An updated systematic review. Am J Ther. 2015 Jan 7. [Epub ahead of print].

    Google Scholar 

  33. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Taiwan Helicobacter Consortium, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial. Lancet. 2013;381:205–13. doi:10.1016/S0140-6736(12)61579-7.

    Article  PubMed  Google Scholar 

  34. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/metronidazole/omeprazole/clarithromycin: A new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter. 1998;3:54–8.

    Article  CAS  PubMed  Google Scholar 

  35. Okada M, Oki K, Shirotani T, Seo M, Okabe N, Maeda K, et al. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol. 1998;3:640–5.

    Article  Google Scholar 

  36. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: Four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109–18. doi:10.1111/j.1523-5378.2009.00671.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23–34. doi:10.2147/CEG.S25419.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kongchayanun C, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter. 2012;17:282–5. doi:10.1111/j.1523-5378.2012.00953.x.

    Article  PubMed  Google Scholar 

  39. Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. World J Gastrointest Pharmacol Ther. 2012;3:1–6. doi:10.4292/wjgpt.v3.i1.1.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, et al. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother. 2014;58:5936–42. doi:10.1128/AAC.02922-14.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145:121–8. doi:10.1053/j.gastro.2013.03.050.

    Article  CAS  PubMed  Google Scholar 

  42. Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, Balboa A, et al. Optimized triple and concomitant therapy for Helicobacter pylori eradication: The OPTRICON study. Aliment Pharmacol Ther. 2015;41:581–9. doi:10.1111/apt.13069.

    Article  CAS  PubMed  Google Scholar 

  43. Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical evaluation of a ten-day regimen with Esomeprazole, Metronidazole, Amoxicillin, and Clarithromycin for the eradication of Helicobacter pylori in a high Clarithromycin resistance area. Helicobacter. 2013;18:459–67. doi:10.1111/hel.12062.

    Article  CAS  PubMed  Google Scholar 

  44. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: A randomised trial. Lancet. 2011;378:507–14. doi:10.1016/S0140-6736(11)60825-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Lim JH, Lee DH, Choi C, et al. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: A randomized pilot study. Helicobacter. 2013;18:180–6. doi:10.1111/hel.12034.

    Article  CAS  PubMed  Google Scholar 

  46. Sharara AI, Sarkis FS, El-Halabi MM, et al. Challenging the dogma: A randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection. United Eur Gastroenterol J. 2014;2:179–88. doi:10.1177/2050640614530919.

    Article  CAS  Google Scholar 

  47. Zullo A, Scaccianoce G, De Francesco V, et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: A pilot study. Clin Res Hepato Gastroenterol. 2013;37:647–50. doi:10.1016/j.clinre.2013.04.003.

    Article  CAS  Google Scholar 

  48. De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for H. pylori eradication: A prospective, randomized study. J Med Microbiol. 2014;63:748–52. doi:10.1099/jmm.0.072322-0.

    Article  PubMed  Google Scholar 

  49. Georgopoulos SD, Xirouchakis E, Mentris A. Is there a nonbismuth quadruple therapy that can reliably overcome bacterial resistance? Gastroenterology. 2013;145:1496–7.

    Article  PubMed  Google Scholar 

  50. Hsu PI, Wu DC, Wu YC, et al. Modified sequential Helicobacter pylori therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139–45. doi:10.1111/j.1523-5378.2011.00828.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Sardarian H, Fakheri H, Hosseini V, et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: A prospective randomized trial. Helicobacter. 2013;18:129–34. doi:10.1111/hel.12017.

    Article  CAS  PubMed  Google Scholar 

  52. Wu JY, Hsu PI, Wu DC, et al. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter. 2014;19:207–13. doi:10.1111/hel.12113.

    Article  CAS  PubMed  Google Scholar 

  53. Oh DH, Lee DH, Kang KK, et al. The efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol. 2014;29:1171–6.

    Article  CAS  PubMed  Google Scholar 

  54. Wang B, Wang YH, Lv ZF, et al. Efficacy and safety of hybrid therapy for Helicobacter pylori infection: A systematic review and meta-analysis. Helicobacter. 2014 Nov 8. doi:10.1111/hel.12180. [Epub ahead of print].

    Google Scholar 

  55. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: Lessons from China. Eur J Gastroenterol Hepatol. 2013;25:1134–40. doi:10.1097/MEG.0b013e3283633b57.

    Article  CAS  PubMed  Google Scholar 

  56. Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: A randomized trial of 10 and 14 days. Helicobacter. 2011;16:295–300. doi:10.1111/j.1523-5378.2011.00857.x.

    Article  CAS  PubMed  Google Scholar 

  57. Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802–7. doi:10.1016/j.cgh.2013.01.008.

    Article  CAS  PubMed  Google Scholar 

  58. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F, Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905–13. doi:10.1016/S0140-6736(11)60020-2.

    Article  CAS  PubMed  Google Scholar 

  59. Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40:171–7. doi:10.1111/apt.12808.

    Article  CAS  PubMed  Google Scholar 

  60. Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic resistance of Helicobacter pylori among male US veterans. Clin Gastroenterol Hepatol. 2015 Feb 11. pii: S1542–3565(15)00122-6. doi:10.1016/j.cgh.2015.02.005.

    Google Scholar 

  61. Marín AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843–61. doi:10.1517/14656566.2013.782286.

    Article  PubMed  Google Scholar 

  62. Gisbert JP, Pérez-Aisa A, Bermejo F, Castro-Fernández M, Almela P, Barrio J, H. pylori Study Group of the Asociación Española de Gastroenterología (Spanish Gastroenterology Association). Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: Time trends in a Spanish multicenter study of 1000 patients. J Clin Gastroenterol. 2013;47:130–5. doi:10.1097/MCG.0b013e318254ebdd.

    Article  CAS  PubMed  Google Scholar 

  63. Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, Chiu YC, Hu ML, Chou YP, Kuo YH, Liang CM, Chiu KW, Hu TH. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study. Helicobacter. 2012;17:374–81. doi:10.1111/j.1523-5378.2012.00960.x.

    Article  CAS  PubMed  Google Scholar 

  64. Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, Xiao S, Graham DY, Lu H. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013;18:373–7. doi:10.1111/hel.12052.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Gisbert JP, Romano M, Gravina AG, Solís-Muñoz P, Bermejo F, Molina-Infante J, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015 Feb 23. doi:10.1111/apt.13128.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hospital San Pedro de Alcantara, C/ Pablo Naranjo s/n, 10003, Caceres, Spain

    Javier Molina-Infante

Authors
  1. Javier Molina-Infante
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier Molina-Infante .

Editor information

Editors and Affiliations

  1. Medical Education Center, Keio University School of Medicine, Tokyo, Japan

    Hidekazu Suzuki

  2. The Royal Perth Hospital, The University of Western Australia and, Western Australia, West Australia, Australia

    Robin Warren

  3. The Royal Perth Hospital, The University of Western Australia and, Western Australia, Australia

    Barry Marshall

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Molina-Infante, J. (2016). Quadruple Regimens for Helicobacter pylori Infection. In: Suzuki, H., Warren, R., Marshall, B. (eds) Helicobacter pylori. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55705-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-55705-0_15

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-55704-3

  • Online ISBN: 978-4-431-55705-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation